Delhi High Court refuses to direct Zydus to disclose manufacturing process of Sigrima: Gireesh Babu, New Delhi Saturday, July 26, 2025, 08:00 Hrs [IST] The Delhi High Court has sa ...

In this video, Nancy U. Lin, MD, highlights practice-changing trials in the HER2-positive metastatic breast cancer space.

FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved ...

TOKYO & BASKING RIDGE, N.J., June 02, 2025--ENHERTU plus Pertuzumab Reduced Risk of Disease Progression or Death by 44% vs. THP as 1L Therapy in Patients w/ HER2 positive mBC in DESTINY-Breast09 ...

ENHERTU® Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 ...

The breast cancer drug pertuzumab when added to Herceptin improved the treatment of women with early-stage, HER-2 positive breast cancer, researchers reported Friday at the annual meeting of the ...

Results: As of October 1, 2009, 37 pts had enrolled; 23 safety evaluable pts (9 in phase 1b and 14 in phase 2) received ≥1 cycle of T-DM1 and P (median of 2 cycles each, ranges 1-8 and 1-6, ...

Enhertu® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line ...

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line ...

Pertuzumab is a monoclonal antibody being studied in early-stage and metastatic HER2-positive breast cancer. It is an investigational HER2-targeted medicine called a HER2 dimerization inhibitor (HDI).

4.5 The committee heard from the clinical experts that pertuzumab with trastuzumab and docetaxel is a very effective treatment, and has been shown to improve overall survival by approximately 16 ...